Community Care Physicians

Albany, New York 12208

0 studies enrolling now · 4 studies all time

What they study most

Bladder Cancer Recurrence, Microscopic or Gross Hematuria, Renal Cell Carcinoma

Studies at this site

• Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence — Stopped early
• Treatment of Advanced Renal Cell Carcinoma With Quinacrine — Withdrawn before enrolling
• Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer — Completed
• Hematuria Evaluation Trial for Subjects With Microscopic or Gross Hematuria to Determine the Absence or Presence of Bladder Cancer — Completed